Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CASI Pharmaceuticals Inc CASI

Healthcare Biotechnology
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its... see more

Recent & Breaking News (NDAQ:CASI)

CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common Stock

PR Newswire March 24, 2021

CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock

PR Newswire March 23, 2021

CASI Pharmaceuticals To Host Business Update Call March 12, 2021

PR Newswire March 11, 2021

Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China Region

PR Newswire March 8, 2021

CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2020 Revenues And Provides Business Updates

PR Newswire February 16, 2021

CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin's Lymphoma Patients

PR Newswire January 28, 2021

CASI Pharmaceuticals Partner, BioInvent, To Host Key Opinion Leader Call On BI-1206 For Relapsed Or Refractory Non-Hodgkin's Lymphoma

PR Newswire January 21, 2021

CASI Pharmaceuticals, Inc. To Present At H.C. Wainwright Bioconnect Conference

PR Newswire January 8, 2021

CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy Designation

PR Newswire December 23, 2020

CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer

PR Newswire December 16, 2020

CASI Pharmaceuticals Announces Partner Juventas Completes $65 Million Financing And Initiates Registration Study For CNCT19 (CD19 CAR-T)

PR Newswire November 18, 2020

CASI Pharmaceuticals Announces Third Quarter 2020 Financial Results

PR Newswire November 9, 2020

CASI Pharmaceuticals To Report Third Quarter 2020 Financial Results And Host Conference Call November 9, 2020

PR Newswire November 5, 2020

CASI Pharmaceuticals Announces Poster Presentation At The 2020 AABB Virtual Annual Meeting

PR Newswire October 2, 2020

CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd

PR Newswire September 29, 2020

CASI Pharmaceuticals, Inc. to Participate in Two Upcoming September Conferences

PR Newswire September 11, 2020

CASI Pharmaceuticals Announces Second Quarter 2020 Financial Results

PR Newswire August 10, 2020

CASI Pharmaceuticals To Report Second Quarter 2020 Financial Results And Host Conference Call August 10, 2020

PR Newswire August 3, 2020

CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common Stock

PR Newswire July 22, 2020

CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock

PR Newswire July 21, 2020